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Objective: The usefulness of any questionnaire in clinical management and research trials
depends on its ability to indicate a likelihood of treatment success during follow-up. The
Minimal Clinically Important Difference (MCID) reflects a clinically relevant change score.
The aim of this study was to estimate the MCID for the Fatigue Assessment Scale (FAS) in
patients with sarcoidosis.
Methods: Outpatients (n Z 321) of the ild care team of the Department of Respiratory
Medicine of the Maastricht University Medical Centre, The Netherlands, participated in this
prospective follow-up study. Anchor-based and distribution-based methods were used to esti-
mate the MCID. Based on the anchor Physical Quality of Life, a Receiver Operating Character-
istic (ROC) was obtained. The distribution-based methods consisted of the Effect Size and
Standard Error Measurement (SEM).
Results: The anchor-based MCID found with ROC was 3.5. The distribution-based methods
showed that the corresponding change scores in the FAS for a small effect was 4.2. The SEM
criterion was 3.6 points change in the FAS.
Conclusions: Based on the anchor-based and distribution-based methods, the MCID is a 4-point
difference on the FAS. This MCID can be used in the follow-up of fatigue (FAS) in clinical trials
and in the management of individual sarcoidosis cases.
ª 2011 Elsevier Ltd. All rights reserved.partment of Medical Psychology, Room P510, Tilburg University, Warandelaan 2, PO Box 90153,
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Fatigue is the most common symptom in sarcoidosis that
often leads to a decreased quality of life (QOL).1e3 Further-
more, fatigue is associated with symptoms of depression,4
cognitive impairment,5 exercise intolerance,6 and stress.7
Because of this substantial influence on the patient’s life,
it is important to appropriately assess fatigue with a valid
and reliable measure in clinical practice as well as in
clinical trials.
Combined with clinical outcomes assessment, measure-
ment of fatigue provides greater insight into suitable
clinical interventions and patients’ response to treatment.
In the absence of an objective measure for fatigue, it is
usually measured by means of self-reported questionnaires.
The Fatigue Assessment Scale (FAS) is a short self-report
questionnaire for measuring fatigue. This instrument has
shown to be a valid and reliable fatigue measure among
sarcoidosis patients.8,9 Several studies found significant
differences in the score of the FAS between subgroups of
sarcoidosis patients.2,5,7,10e12 Although these differences
were statistically significant, they may be irrelevant from
the patients’ point of view.
A limitation of questionnaires in general is that their
statistical scores do not provide directly a clinical inter-
pretation. The minimal clinically important difference
(MCID) has been developed as a measure for the smallest
change score of interest which patients perceive as rele-
vant.13 Treatment effects that exceed the MCID denote
clinical significance and support implementation into clin-
ical practice. Thus, the MCID indicates that the minimal
change in fatigue scores across time of individual patients
represents a clinically relevant difference, thereby helping
clinicians to interpret the clinical meaning of changes on
fatigue scores of individual patients. In addition, the MCID
is relevant in both the planning of clinical trials and inter-
pretation of the results when evaluating outcomes of
intervention studies using the FAS. Till now, no MCID has
been established for this fatigue questionnaire in sarcoid-
osis. Moreover, the MCID criteria that are already estab-
lished for fatigue questionnaires in other populations14e17
cannot be applied to a sarcoidosis population, because
the MCID criteria vary by population.18
Therefore, the aim of this study was to estimate the
MCID for the FAS in patients with sarcoidosis in order to
evaluate clinical outcome of interventions.
As recommended by Revicki et al.19 we have employed
both anchor-based and distribution-based methods to
establish the MCID of the FAS. Distribution-based and
anchor-based methods have been used to determine
a MCID in fatigue.14e17 The anchor-based method com-
pares measures of fatigue to other measures or phenomena
that have clinical relevance. The distribution-based
method is based on the characteristics of the particular
patient population, such as sample variability and preci-
sion of the questionnaire.20 An anchor-based approach
was chosen for this study in order to link the change in
fatigue with a meaningful external anchor. In addition, two
distribution-based methods were used to evaluate the
responsiveness of the MCID found with the anchor-based
approach.Methods
Patients
All sarcoidosis outpatients (nZ 588) of the ild care team of
the Department of Respiratory Medicine of the Maastricht
University Medical Centre (MUMCþ), a tertiary referral
center in The Netherlands, were asked to participate. The
flowchart of the patient participation is shown in Fig. 1.
Patients were diagnosed with sarcoidosis based on consis-
tent clinical features and bronchoalveolar lavage (BAL)
fluid analysis results according to the World Association of
Sarcoidosis and Other Granulomatous Disorders (WASOG)
guidelines.21 The exclusion criteria were poor expression in
the Dutch language (nZ 3), relevant co-morbidity, such as
malignancy (n Z 7), dementia (n Z 1), and a history of
psychiatric illness (n Z 2).
Procedure
The patients received information about the study by mail
and were asked to return an informed consent form when
they were willing to participate in the study. Patients who
agreed to participate received the first set of question-
naires in May 2007 and were asked to return the completed
set to the hospital in an enclosed envelope. In May 2008 the
same patients received a second set of questionnaires with
an envelope. The most common reason for not completing
the second set of questionnaires was ‘insufficient time’.
The data were collected by the ild care team. The Medical
Ethical Committee of the MUMCþ approved the study
protocol and written informed consent was obtained from
all patients.
Measures
The patients were sent questionnaires at baseline and after
12 months. The patients completed the Fatigue Assessment
Scale (FAS)8 to assess the change in fatigue during the one-
year follow-up. For the anchor-based method, the change
in physical quality of life (Physical QOL) across time was
assessed with the World Health Organization Quality of Life
BREF (WHOQOL-BREF).22 This anchor was chosen because
previous research found strong associations between the
FAS and this instrument in sarcoidosis.3
The FAS is a 10-item self-report fatigue questionnaire.
The reliability and validity of the FAS are good, also in
sarcoidosis patients.8,9 The response scale is a 5-point
Likert scale (1 never to 5 always). Total scores on the FAS
can range from 10 to 50, with high scores indicating more
fatigue. Consequently, possible changes in FAS scores of
patients could range from 40 to 40 between baseline and
follow-up.
The domain ‘Physical Health’ of the WHOQOL-BREF was
used for the anchor Physical QOL. This anchor was based on
the change score in the domain Physical Health during the
one-year follow-up period. The WHOQOL-BREF is a 26-item
instrument to assess quality of life from the patients’
perspective.22 The content validity, construct validity,
and the reliability of the WHOQOL-BREF are good.23,24
Figure 1 Flowchart of patient selection.
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questions: ‘To what extent do you feel that physical pain
prevents you from doing what you need to do?’, ‘How
much do you need any medical treatment to function in
your daily life?’, ‘Do you have enough energy for everyday
life?’, ‘How well are you able to get around?’, ‘How
satisfied are you with your sleep?’, ‘How satisfied are you
with your ability to perform your daily living activities?’,and ‘How satisfied are you with your capacity for work?’.
The response scale of the domain Physical Health is
a 5-point Likert scale (1e5) and scores can range from 4 to
20, with high scores indicating a better Physical QOL.22
Consequently, change scores on the anchor Physical QOL
between baseline and follow-up could range from 16 to 16.
Statistical procedures
Patients who dropped-out after the baseline measurement
and patients who remained in the study were compared on
demographical (sex, age, ethnicity), clinical (lung function
tests, radiographic staging, (extra) pulmonary involvement,
time since diagnosis), and psychological variables (FAS total
score, WHOQOL-BREF domain scores) by means of t-tests
and chi-square tests.
Change scores for the FAS and the anchor were calcu-
lated by subtracting the baseline score from the 12-month
score. A positive change on the anchor describes an
improvement whereas a positive change on the FAS indi-
cates an increase in fatigue. Because the different meaning
of a positive change may complicate the interpretation of
the results, the sign of the FAS change score was reversed,
so that a positive change score represents an improvement
(decline in fatigue).
As recommended by Revicki et al.19 both distribution-
based and anchor-based methods were used to estimate
the minimal clinically important difference.
Distribution-based method
Two distribution-based methods were used to estimate the
MCID for the FAS. According to Norman et al.,25 an effect
size (ES) of 0.5 approximates the threshold of discrimina-
tion for changes in health-related quality of life for chronic
diseases. Therefore, the expected change scores in the FAS
were calculated for an effect size of 0.5 to estimate the
minimal change.26 The corresponding change scores on
the FAS (Δx12) were the product of these indices and the
standard deviation (SD) at baseline, i.e., Δx12Z ES ) SDx1.
In addition, the Standard Error Measurement (SEM)27,28
was used to identify the minimal clinically important
change in the FAS. The SEM was calculated to identify the
minimal clinically important change using the revised
Jacobson formula.29,30 An observed change that exceeded
the standard measurement error was considered to reflect
a change. Patients with a score that did not exceed the
measurement error were considered to be stable. In
addition, patients were considered to have a minimally
improved or minimally worsened fatigue, if their score
increased or decreased one-SEM, respectively.
Anchor-based method
Concerning the anchor-based method, Pearson’s correla-
tions were calculated to measure whether the change score
of the anchor Physical QOL was associated with the change
score of the FAS. Revicki et al.19 recommended a correla-
tion threshold of 0.30 between an anchor and patient-
reported outcome measure such as QOL, to establish
a MCID.
Subsequently, patients were divided into one of three
groups: improved, stable, or worsened Physical QOL.
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ened in Physical QOL if the change score (between baseline
and follow-up) exceeded the measurement error of the
WHOQOL-BREF domain Physical Health.27e30 In addition,
patients with a score that did not exceed the measurement
error were considered to be stable in Physical QOL.
Frequencies and means were calculated for each group of
the anchor Physical QOL.
The receiver operating characteristic (ROC)31 method is
another anchor-based method that was used to estimate
the MCID.32 For this method, the FAS was considered as the
diagnostic test and the anchor Physical QOL functioned as
the golden standard. The anchor Physical QOL distinguished
persons who improved or worsened from persons who
remained stable on Physical QOL. Additional ROC curves
were obtained for the anchor change score with a CI95%.
This change score is the smallest change that can be
considered above the measurement error with a 95% level
of confidence.33 These change scores were calculated by
multiplying the change scores of the anchor by 1.96.
The ROC was obtained by plotting the sensitivity against
1-specificity for each possible FAS change score. The area
under the ROC curve represents the probability that FAS
scores will correctly discriminate between patients who
improved and worsened on Physical QOL. Probabilities
range from 0.5 to 1, with 0.5 representing the ability to
discriminate on chance and 1 representing the ability to
correctly discriminate all the patients. An area under the
curve of 0.7e0.8 is considered acceptable and an area of
0.8e0.9 is considered excellent.34 The ROC cut-off point is
the value for which the sum of percentages of true positiveTable 1 Descriptive statistics of the participants and dropouts.
Participants n Z 321
Demographics
Sex: male% 55.8
Ethnicity: Caucasian/African descent/
Asian/other %
95.6/3.1/0.3/0.9
Age (range in years) 48.5  10.8 (28e79)
Medical variables
Time since diagnosis (range in years) 7.8  7.7 (0e65)
Multisystemic involvement % 48.0
Radiographic stage: 0/I/II/III/IV % 42.6/8.2/23.5/11.6/1
FVC 99.4  19.4
FEV1 90.2  22.4
DLCO 82.2  17.8
Psychological variables
Fatigue Assessment Scale score 29.5  8.4
Quality of life:
Overall Facet 5.9  1.6
Physical Health 12.5  3.1
Psychological Health 13.8  2.5
Social Relationships 15.4  2.9
Environment 15.4  2.5
DLCO Z Diffuse capacity of the lung for carbon monoxide; FEV1 Z Fo
a Data are expressed in mean  standard deviation or in percentag
b All statistical values are not significant.and true negative classifications is largest (sensitivity þ
specificity). Because we are interested in the minimal
change, the smallest value was chosen as the cut-off point
when several options were found for the largest sum
(rounded to two decimals). This optimal cut-off point is the
estimation of the anchor-based MCID for the FAS.Results
Demographical, clinical, and psychological characteristics
at baseline are presented in Table 1. No differences were
found in these variables between the patients who
dropped-out of the study and the patients remaining in the
study.Anchor-based method
The anchor Physical QOL was found to be eligible for
estimating a MCID for the FAS, because the correlation
between the change scores of the FAS and the anchor
(r Z 0.47 (p < 0.001, CI95% 0.38e0.55)) exceeded the
threshold of rZ 0.30.19 The measurement error of Physical
Health was j1.63j. Based on this value, the three groups of
the anchor Physical QOL (worsened, stable, and improved)
were distinguished: a change score of 1.63 or lower for
patients who had worsened (n Z 62), a change score
between 1.63 and 1.63 for patients who remained stable
(nZ 186), and a change score of 1.63 or higher for patients
who had improved (n Z 67). The corresponding meana
Dropouts n Z 122 Statisticsb
48.4 c2 (1, N Z 443) Z 1.7
93.4/3.3/0.8/2.5 c2 (4, N Z 442) Z 2.1
46.8  12.1 (19e80) t (441) Z 1.2
7.2  7.9 (0e42) t (439) Z 0.8
48.3 c2 (1, N Z 439) Z 0
4.1 34.4/9.8/27.0/14.8/13.9 c2 (4, N Z 441) Z 2.9
96.8  20.6 t (429) Z 1.2
87.1  21.9 t (431) Z 1.2
79.6  16.7 t (431) Z 1.4
28.8  8.4 t (433) Z 0.8
6.2  1.6 t (443) Z 1.6
12.8  3.1 t (430) Z 1.0
13.8  2.6 t (431) Z 0.1
14.5  3.0 t (430) Z 0.1
15.2  2.6 t (432) Z 0.7
rced Expiratory Volume in 1 s; FVC Z Forced Vital Capacity.
es.
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anchor group, respectively.
The ROC was obtained to estimate the anchor-based
MCID for the FAS for both improved patients and worsened
patients. The area under the ROC curve for the improved
patients was 0.6, this means that the ability of the FAS to
discriminate patients who improved in Physical QOL was
just above chance level. Thus, the cut-off value for a MCID
in the FAS was 3.5 points, which corresponded to an optimal
balance between a sensitivity of 45% and a specificity of
81%, e.g., 45% of the patients were correctly identified as
improved and 81% of the patients were correctly identified
as not improved.
When the analysis was repeated with patients who were
worsened versus patients who remained stable in Physical
QOL, the area under the curve was 0.7. This means that the
FAS fairly discriminated patients who worsened in Physical
QOL. The cut-off value of the FAS is 3.5, which corre-
sponded to a sensitivity of 82% and a specificity of 51%.
When selecting the patients with an anchor change score
in Physical QOL with a 95% interval, the same cut-off of 3.5
points change on the FAS was found for both the improved
and the worsened patients. The area under the curve was
0.8 for the improved patients, and 0.9 for the worsened
patients. This means that the ability of the FAS to
discriminate patients who changed in Physical QOL was
good. In addition, the sensitivity and specificity increased
to 79% and 84% for the worsened patients and 71% and 78%
for the improved patients, respectively.
Distribution-based methods
The corresponding minimal change on the FAS for an effect
size of 0.5 was 4.2.Figure 2 Minimal clinically important diffThe reliability coefficient Cronbach’s alpha of the FAS
was 0.9, resulting in a one-SEM of 3.6. This reflects the
cut-off point of a statistical minimal change in the FAS.
Minimal clinically important change
In sum, for the anchor-based method, mean scores of 3.8
for the worsened patients and 3.0 for the improved patients
were found, and the ROC cut-off was j3.5j. For the
distribution-based method, the ES was j4.2j and the SEM
was j3.6j. These estimates for the minimal clinically
important changes found with both methods are rounded
to 4 points change on the FAS, because the FAS is measured
in whole points. This cut-off of the minimal clinically
important change is represented in Fig. 2 with two dashed
lines. Patients who scored above or below these lines were
considered to be either minimally improved or minimally
worsened in fatigue, respectively.
Discussion
The FAS is a validated fatigue questionnaire used in the
management and follow-up of sarcoidosis patients as well
as an outcome measure in clinical trails. However, until
now a minimal clinically important difference (MCID) was
lacking. Therefore, the aim of this study was to determine
the MCID of the FAS in sarcoidosis patients. To estimate the
MCID both anchor-based and distribution-based methods
were used in this study because they are complementary,
i.e., each has different advantages.20 Both methods
revealed similar results. The MCID was estimated on
a change of 4 points indicating that when the FAS scores of
a patient change between two time points with at least
4 points, this change in fatigue is clinically meaningful.erence of the Fatigue Assessment Scale.
MCID for the FAS in sarcoidosis 1393Anchor-based method
The anchor Physical QOL takes into account Physical Health
from the patients’ perspective. Based on the anchor Phys-
ical QOL, the minimal change was estimated at 3.5 points
change on the FAS by means of a ROC curve. The same
threshold for a minimal clinically important change in
fatigue was found for patients with a large and a small
change in Physical QOL, which strengthens the criterion for
change. The high percentages provided by the ROC curve
for the anchor with a 95% confidence interval indicate that
the chance to incorrectly define a patient as changed or
unchanged is low when using a threshold of 4 points on the
FAS (rounded). This may be important when the negative
effects of group assignment are large, e.g., when treat-
ment has side-effects or is expensive.
Other studies applied anchor-based methods, based on
non-clinical anchors to determine a MCID for fatigue
instruments.13,14 Pouchot et al.15 matched the scores of the
fatigue measures with the self-reported ratings of fatigue
on a global scale. A limitation of this method is that the
differences between patients may be incomparable to
longitudinal changes within patients. Moreover, a global
rating is frequently used in anchor-based methods, but
coincides with several difficulties: patients have to rate the
change in fatigue in an extended period of time in the past,
these retrospective ratings are susceptible for recall bias
and current mood states. In addition, little information is
available about the validity and reliability of these global
ratings. Furthermore, depending on the magnitude of the
correlation with fatigue, the global ratings do not explain
the total variance in fatigue.20 Purcell et al.14 determined
in a follow-up study MCID scores for the Multidimensional
Fatigue Inventory using the anchors Health-related Quality
of Life, performance status, and productive hours.
No associations between performance status or produc-
tive hours and fatigue have been reported in sarcoidosis.
Therefore, in the current study, we chose to select an
anchor from the WHOQOL-BREF, which is a validated and
reliable instrument23,24 and associated with fatigue in
sarcoidosis.2 Clinical anchors were not selected, because
previous studies showed no significant relationships
between the FAS and widely used medical data in sarcoid-
osis.2 In addition, in this study longitudinal changes within
patients were examined to evaluate the development of
fatigue.
Distribution-based methods
An advantage of the distribution-based methods is that they
provide a MCID which exceeds random variation.20 Wyrwich
et al.27,28 and Rejas et al.35 showed that the SEM criterion is
a promising measure to estimate the MCID, because the SEM
relies on the precision of the instrument, is independent of
sample size, and takes spurious change due to measure-
ment error into account. Moreover, the SEM criterion is
a frequently used measure in studies which determined
a minimal change in diseases similar to sarcoidosis.36e40 In
addition, the effect size represents the individual change,
also is independent of sample size,20 and also is commonly
used to determine a change.41,42 In this study, it appearedthat the MCID based on the anchor approximated the MCID
found with the distribution-based methods. The similar
results from both the anchor-based and distribution-based
method might suggest that the estimation for the MCID is
robust.
Systemic manifestations are considered important in
sarcoidosis. The extent of physiological impairment or organ
system loss of function is still applied to classify the severity
of sarcoidosis: most often still based on stratification of
respiratory functional impairment.21,43 It has been widely
accepted now that an integral assessment frame work
of quality of life, incorporating physiological functioning,
complaints like fatigue, exercise impairment and health
status, improves conceptual insight in the impact of
sarcoidosis on patients’ lives and offers the clinician avenues
in individual management.6 Therefore, in the management
of sarcoidosis it is mandatory to have insight in the MCID of
the validated fatigue questionnaire in sarcoidosis: the FAS.
The results of this study are relevant for researchers and
clinicians who want to assess clinically important changes
in fatigue in sarcoidosis patients. Researchers should
consider clinical significance from the patients’ perspec-
tive, as well as statistical significant results. The MCID also
improves conceptual insight in the impact of sarcoidosis on
patients’ lives. Moreover, the MCID is a clinically important
concept, as it may assist clinicians with the interpretation
of observed changes in the FAS and may influence the
perceived success of an intervention. In addition, the MCID
could have implications for the design of clinical trials in
terms of the selection of a useful clinical outcome
measure. Therefore, in the management of sarcoidosis it is
recommended to have insight in the MCID of the validated
fatigue questionnaire in sarcoidosis, i.e., the FAS. The MCID
identified in this study is aimed to improve the clinical
interpretation of changes in sarcoidosis-associated fatigue
as measured by the FAS.
One limitation of this studymay be that the patients were
recruited in a tertiary referral centre, which may have
caused selection bias and, therefore, the results may be not
representative for every sarcoidosis patient. Consequently,
we recommend using the MCID found in this study as
a guideline. A limitation of the Standard Error Measurement
is that this approach relies on the assumption that
measurement error is constant across the range of possible
scores.20 For future studies it is important to take into
account that a change of one point may be different for a
patient who shows an impaired energy level at baseline in
contrast to a patient who shows little or no impairment.
In conclusion, using various methods the present study
showed that a change in a patient’s FAS score across
time of at least 4 represents a clinically important
difference, i.e., the fatigue of the patient has increased
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